Lyell Immunopharma (LYEL) EBITDA Margin (2020 - 2026)
Lyell Immunopharma recorded quarterly EBITDA Margin of 1220200.0% in Q1 2026, up 47.96% quarter-over-quarter from 2344700.0% in Q4 2025, and down 47265714.0% year-over-year from N/an in Q1 2025.
Lyell Immunopharma's EBITDA Margin history runs 7 years deep, the most recent figure standing at 1220200.0% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 47265714.0% year-over-year to 1220200.0%; the TTM figure through Mar 2026 stood at 795396.77% (down 28161216.0% YoY), while the FY2025 annual figure was 762491.67%, down 20083757.0% from the prior year.
- EBITDA Margin came in at 1220200.0% for Q1 2026 at Lyell Immunopharma, up from 2344700.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 12.4% in Q4 2022 to a low of 2396633.33% in Q3 2022.
- A 5-year average of 747221.25% and a median of 352323.08% in 2024 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin plunged 239485428 bps in 2022 and surged 219801333 bps in 2023, its largest moves.
- Lyell Immunopharma's EBITDA Margin stood at 12.4% in 2022, then slumped by 3215894 bps to 398792.31% in 2023, then tumbled by 339 bps to 1749127.27% in 2024, then slumped by 34 bps to 2344700.0% in 2025, then surged by 48 bps to 1220200.0% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 1220200.0%, 2344700.0%, and 258013.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -1,220,200.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,220,200.00% |
| Dec 31, 2025 | -2,344,700.00% |
| Sep 30, 2025 | -258,013.33% |
| Jun 30, 2025 | -534,812.50% |
| Mar 31, 2025 | -747,542.86% |
| Dec 31, 2024 | -1,749,127.27% |
| Sep 30, 2024 | -127,723.53% |
| Jun 30, 2024 | -352,323.08% |
| Mar 31, 2024 | -2,032,566.67% |
| Dec 31, 2023 | -398,792.31% |
| Sep 30, 2023 | -198,620.00% |
| Jun 30, 2023 | -231,074.07% |
| Mar 31, 2023 | -97,290.77% |
| Dec 31, 2022 | -12.40% |
| Sep 30, 2022 | -2,396,633.33% |
| Jun 30, 2022 | -106.53% |
| Mar 31, 2022 | -13,222.60% |
| Dec 31, 2021 | -3,021.40% |
| Sep 30, 2021 | -1,779.06% |
| Jun 30, 2021 | -2,385.27% |
| Mar 31, 2021 | -2,255.05% |
| Dec 31, 2020 | -1,695.24% |
| Sep 30, 2020 | -3,394.11% |
| Jun 30, 2020 | -3,224.86% |